Allogeneic iNKT Cell Therapy (agenT-797) After SCT
United States22 participantsStarted 2026-10
Plain-language summary
The goal of this clinical trial is to learn if agenT-797 is safe to use on people undergoing allogenic hematological stem cell transplantation (SCT). The main questions it aims to answer are:
* Is agenT-797 safe to use?
* What medical problems do participants have when taking agenT-797?
Participants will receive an infusion of agenT-797 about 7 days after their allogenic SCT.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥18 years at the time of consent
* Adult patients anticipated to get an allogeneic hematopoietic cell transplantation (allo-SCT)
* All donor types are accepted (MMUD \[mismatched unrelated donor\], MUD \[matched unrelated donor\], MSD \[matched sibling donor\], haploidentical)
* All conditioning regimens will be accepted (MAC \[myeloablative conditioning\], RIC \[reduced-intensity conditioning\], NMAC \[non-myeloablative conditioning\])
* Karnofsky Performance Scale (KPS) \> 70
* Eligible Diagnoses:
* Acute myeloid leukemia (AML) with intermediate/high-risk features or relapsed disease
* Chronic myeloid leukemia (CML) in accelerated or blast phases
* Myelodysplastic syndrome (MDS) with intermediate/high-risk features
* Acute lymphoblastic leukemia (ALL) with high-risk features or relapsed disease
* or any patients undergoing allogeneic stem cell transplant (allo-SCT) as standard of care could be eligible
Exclusion Criteria:
* Excluded Diagnoses: Primary Myelofibrosis in the dose escalation phase and could be included in the dose-expansion phase
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number Of Participants With Treatment-related Adverse Events
Timeframe: Baseline through Day 29 post cell infusion
2
Number Of Dose-limiting Toxicities
Timeframe: Baseline through Day 29 post cell infusion